4 results
To determine whether aleglitazar reduces cardiovasculair mortality and morbidity (defined as non-fatal myocardial infarction (MI) and non-fatal stroke) in patients with a recent ACS event and type 2 diabetes.
The results of this study will give better insights in the role of ADMA in the development of systemicendothelial dysfunction and the relation with mild renal insufficiency.
The results of this study will give better insights in the role of ADMA in the development of systemic endothelial dysfunction.
The main objective of the trial is to evaluate whether maintenance trabectedin given after 6 cycles of doxorubicin first-line therapy for advanced or metastatic STS prolongs progression-free survival (PFS) as compared to an observational approach.…